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The release rate of a drug molecule from a porous support depends on a large num-
ber of factors, including support characteristics, surface functionalization (procedure and
linker type), drug features, biological receptor fluid characteristics, and release condi-
tions. Model-based (in-silico) modulation of the release rate through influential parame-
ters can help in designing an optimized delivery system for a specific drug action. To
prevent biased predictions, a dynamic mechanism-based model was adopted, by in-
cluding kinetic terms related to surface adsorption-desorption, diffusion in pores, and
external diffusion of the drug to the body fluid. Exemplification is made for the case
of a functionalized silica MCM-41 support with a tunable pore size distribution and
functionalization possibilities with hydrophobic (triethoxyvinylsilane, VTES) or hydro-
philic (3-aminopropyl triethoxysilane, APTES) linkers. Variation of several structural pa-
rameters, referring to the average pore size, initial drug load, and linker proportion on a
bi-functionalized support, pointed out the strong nonlinear relationships between the pro-
cess variables and the release rate.
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Introduction
Over the last decades, extensive experimental
efforts have been made for studying and designing
optimized drug delivery systems, using both natural
and artificial materials as drug carriers. Porous (sil-
ica, alumino-silica, polymers, gels, carbon based),
amorphous colloidal, or hybrid inorganic-organic
supports open a wide range of options to develop
an efficient release system.1 Surfaces modified by
(multi-)functionalization are used to control the
release of drugs, proteins, and other bioactive
compounds into body fluids (gastric, intestinal, or
plasma) with a wide range of applications in medi-
cine and industrial area.2–5 Various alternatives of
drug(ligand)-linker-support systems have been in-
vestigated, trying to “program” the drug release
into a target environment.
Currently, optimized drug delivery systems can
be designed for every specific molecule and desired
action.2 In the pre-programmed drug delivery, the
release rate is adjusted by the system characteristics
controlling the diffusion in the polymeric/inorganic
matrix, across the support membrane, or from a mi-
cro-reservoir containing a homogeneous dispersion
/ heterogeneous suspension of drug particles in a
lipophilic/hydrophilic polymeric matrix / solution.
In the activated drug delivery systems, the release
rate is induced and controlled by physical (osmotic
or hydrodynamic pressure, mechanical, magnetic,
ultrasonic forces), chemical (pH, ionic strength, re-
dox agents), or biochemical (enzymes) means. In
the feedback-regulated release, various triggering
agents, present in the body fluid, activate and con-
trol the drug release rate by a slow erosion of the
functionalised membrane, by controlling the mem-
brane permeability, or simply by chemical reaction
with the support-ligand system.6 Modern technolo-
gies of developing molecularly imprinted supports
(MIP, with covalently or non-covalently coupled
drug) are currently used for designing intelligent
drug release systems, feedback controlled or site
targeting, triggered by a specific agent or by MIP
binding to a specific tissue.7 Such a highly con-
trolled release is the result of designing systems
with molecular recognition properties, and of ap-
plying specific preparative strategies that place
binding or functional groups at defined positions in
imprinted sites of the support.8
Among carriers, ordered mesoporous supports
proved to be very suitable for designing a controlled
release system, due to excellent adsorption proper-
ties, a high specific surface area and porosity, high
stability, tunable pore size with narrow distribution,
biocompatibility, easy functionalization allowing to
modulate the release rate.5,9,10 Functionalization of
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the support with suitable crosslinkers allows incor-
porating organic / hybrid species in the porous sup-
port for bonding guest molecules, thus changing dra-
matically the support surface properties (hydrophi-
licity, hydrophobicity, resistance to surface attack
agents).1 Grafting the support surface with passive or
active groups, surface coating, or the use of co-con-
densation reactions are the most common methods
for surface functionalization via covalent bonding of
organic groups. In the post-synthesis method, graft-
ing the silanol groups with hydrophobic alkyl or
phenyl groups, or with hydrophilic aminopropyl or
mercaptopropyl groups, is a very flexible technique
to tailor the pore and particle size, as well as the sur-
face polarity. The direct synthesis (“one-pot” reac-
tion) involves co-condensation of tetraalkoxysilane
with organoalkoxysilanes in the presence of a
surfactant leading to hybrid inorganic-organic matri-
ces with a more homogeneous surface coverage but
with the disadvantage of breaking the matrix integ-
rity for high coverage percentages.1,11 Multi-func-
tional surfaces can also be obtained, although the lo-
cation of different functional groups cannot be as
much controlled as by grafting process.
One particular class of silica supports are the
mesoporous MCM and SBA, intensively used as
carrier matrix for a large number of drugs, such as
antibiotics of different generations (e.g. gentamicin,
erythromycin, tetracycline, etc.), anti-inflammatory
drugs (aspirin, ibuprofen, diflunisal, naproxen), anti-
cancer drugs (e.g. irinotecan, cisplatin, taxotere,
taxol, navcelbine, methotrexate), vitamins, etc.5,9,12,13
The advantage of these supports is coming from
the very ordered structure including regular and
straight pores (e.g. hexagonal array with pore sizes
of 20–50 Å for MCM-41), a high porosity
(0.6–0.8), high BET surface area (500–1260 m2
g–1), and a high drug uptake capacity.11,13–16 Being
covered with siloxane bridges and free silanol
groups, the surface availability for a certain drug
can be adjusted by functionalization with hydro-
phobic / hydrophilic silylating agents or reactive
groups (e.g. nitriles, alkylthiols, alkyl amines,
alkylsilane linkers).1,10,11,17 The release rate can also
be changed by pore size modulation using various
surfactants,14,18 by increasing the adsorption capac-
ity with varying the Si/Al ratio in hybrid supports,19
or by eventually coating the support with a suitable
membrane.1,12
To design an optimized delivery system for a
specified drug, steady experimental investigations
try to separate the contribution of influential fac-
tors: support structural properties (composition,
morphology, specific surface area, porosity / pore
volume, tortuosity, pore sizes and their distribu-
tion), drug features (structure, solubility, stability,
uptake on the support, diffusivity), linker charac-
teristics (structure, hydrophilicity / hydrophobicity,
amount), biological fluid interacting with the
drug-linker-support system (composition, redox /
ionic activity, presence of activating agents), release
conditions (pH, temperature, stirring).2,6,10,13,20,21 La-
boratory experiments in a synthetic medium are
usually employed, even if they cannot reproduce
the whole system complexity, thus leading to lim-
ited interpretations.
To better correlate the results, various kinetic
and thermodynamic models have been proposed, of
complexity depending on the available information
and utilization scope. Based on these, in-silico de-
sign of an optimized delivery system can be devel-
oped leading to: i) a considerable reduction in the
experimental effort by using the predictive capacity
of an adequate and robust model; ii) possibility to
highlight the physico-chemical-biological influen-
tial factors and their individual action mode on the
release rate and equilibrium state; iii) possibility to
correlate the system characteristics with the model
parameters; iv) possibility to direct the experimen-
tal effort toward the most favourable delivery con-
figuration for a specified drug and action type.
Even if experimental checks of the model predic-
tions remain an essential issue, the in-silico activi-
ties can considerably reduce the design effort.
For a precise prediction of the process dynam-
ics [that is the time dependent mass of released
drug until a certain time M(t)], an adequate mathe-
matical model has to be employed. The use of sim-
ple empirical models for the diffusion in support or
membrane, for swelling systems, or for a che-
mically controlled release (e.g. power-law model
M t M kt n( )   of n-th order, growing exponen-
tial, or models of zero-, first-, or second-order ap-
parent rate; review of Maria & Luta6) usually pres-
ent inconsistent parameters, dependent on the initial
drug load, and requiring additional statistical corre-
lations with the structural characteristics of the
drug-support system.2,3,5,14,21–24 Alternatively, a
mechanistic based dynamic model, including terms
related to the physico-chemical adsorption-desorp-
tion on the surface, internal and external diffusion
steps, and structural/operating parameters can offer
more precise, robust and interpretable predictions.
The model should be able to predict, under sink or
non-sink conditions, the variation of drug concen-
tration in the bulk phase, with rate constants inde-
pendent of the initial drug dose or fluid concentra-
tions. For instance, various diffusion models have
been elaborated in one or several phases (support
matrix, pores, coating membrane, external liquid),
by using Fick-type equations solved for different
geometries (thin sheet, rectangular parallelepiped,
cylinder of finite or infinite length, sphere), with
known initial (uniform or non-uniform field distri-
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bution in the solid) and boundary conditions (at the
solid-liquid or membrane interface with an external
diffusion layer or with bulk liquid).2,6,13,22,25 By in-
cluding parameters that quantify the system struc-
ture and environment characteristics, such models
are suitable to in-silico modulate the system proper-
ties for obtaining a desired drug release.
Recently, Maria et al.13,26 proposed a compart-
mented mechanistic model (denoted here as “Ex-
tended Kinetic Model” – EKM), by including a
minimum number of terms describing the surface
physico-chemical interactions between drug and
(un)functionalized surface, the Fickian diffusion in
pores and in the external liquid film. The model
was proved to adequately represent the release of
various biological active molecules, such as irinote-
can (but also some cephalosporines, anti-TBC, and
other drugs) from mesoporous silica carriers, with
the advantage of including consistent and interpret-
able parameters, independent on the initial drug
load. The EKM includes parameters related to the
support morphology (specific surface area, porosity,
pore volume, tortuosity, average pore size), and rate
constants related to the support-linker chemical
structure, functionalization type, and operating con-
ditions.
The aim of this paper is to check the possibility
of using the EKM to in-silico modulate the drug re-
lease rate by varying structural and operating condi-
tions, leading to design a drug delivery system with
a controlled release. Exemplification is made for a
silica MCM-41 support, functionalized with hydro-
phobic triethoxyvinylsilane (VTES) or hydrophilic
3-aminopropyl triethoxysilane (APTES) linkers,
and used for the release of irinotecan into a syn-
thetic intestinal fluid. The study will be focus on
modulating the internal resistance parameters that is
the average pore size, initial drug load and linker
proportion on a bi-functionalized support. The
model is applied to spherical support particles, but
other configurations (e.g. porous cylindrical tablets,
or thin films) can be easily approached by evaluat-
ing the particle effectiveness and mass transfer co-
efficients with recommended relationships from lit-
erature.27,28
Drug adsorption-desorption model
The adopted EKM for describing the drug ad-
sorption-desorption on porous solid supports (with-
out membrane or swelling properties)13,26 considers
three drug “forms”, belonging to three homoge-
neous phases in contact: the “free” drug (A f
s ) mov-
ing in the liquid filling the pores; the “bonded”
drug (Ab
s) absorbed on the solid matrix sites (di-
rectly or via a linker molecule L); the “external”
drug (Al ) dissolved in the external liquid / bulk
convective phase (see schema of Figure 1; A de-
notes the concentration of the drug species referred
here to the liquid volume, but solid volume or mass
can be used as well). Drug adsorption-desorption
occurs until the equilibrium among phases is
reached. For a soluble drug in the receptor liquid,
the EKM includes the following terms (Table 1, see
also the Appendix of Maria et al.26):
i) adsorption-desorption reactions on the










, the triggering forces being
the drug adsorption potential (proportional to the




, max ), and the
drug desorption potential (proportional to the fluid
unsaturation degree, 	 l f f
sA A 
max ). The model
assumes that adsorption sites are uniformly distrib-
uted on the homogeneous surface, being equally ac-
cessible to the drug molecules, the drug being dis-
posed in a mono-molecular layer on the active sites
(adsorption on the pore walls is neglected, K p  1).
ii) diffusional flow rate of the drug through the
pore cross-section at interface (J diff s, ), the transport
resistance in the particle being synthetically ex-
pressed by the effectiveness factor (). Particle ef-
fectiveness is evaluated by means of Thiele
modulus (), which is dependent on the particle di-
ameter (d p), rate constants (k k1 2, ), and the effec-
tive diffusivity in pores (D A ef, , see its evaluation in
Table 1; Knudsen and surface diffusion are ne-
glected, the former being of three orders of mag-
nitude higher than the molecular diffusivity).
According to this method, the drug concentration at
the solid surface (A f
sup
) is considered only function
of time, its values resulting from solving the
steady-state equality of fluxes through the solid sur-
face and the external liquid film.
iii) diffusion flux of the drug in the external
liquid film surrounding the support particle to/from
the receptor body fluid (considered homogeneous)
due to the concentration gradients. Evaluation of
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F i g . 1 – The hypothetic mechanism of drug (D) adsorp-
tion-desorption on functionalized surface sites (S) with linkers
(L1,L2) and the drug diffusion in the porous solid support
(adapted from Maria et al.13)
the liquid-solid mass transfer coefficient (on liquid
side, ks) is made following the Table 1 rule. It is to
notice that, for most of the organic drug molecules,
the internal drug transport resistance is much higher
than those in the external liquid film (that is
D k dA ef s p,  ), so generally the external resis-
tance to the mass transfer in the well-mixed bulk
liquid is negligible.
The mass balance equations can be reduced by
using the particle effectiveness factor and A f
sup
at in-
terface instead of internal A f
s (see details of Maria
et al.26). By using a stiff integrator, with simulta-
neously fulfilment of flux equality at interface on
every small time increment, the solution of the dif-
ferential-algebraic model was obtained.
By solving the EKM for every defined delivery
system, the dynamics of drug concentrations on the
support, at the solid-liquid interface, and in the ho-
mogeneous (well-mixed) bulk-liquid is thus ob-
tained. In contrast to the semi-empirical or overall
diffusional models,13,25 the EKM advantage is com-
ing from its relative simplicity and capacity to pre-
dict the drug concentration evolution in every sys-
tem compartment/phase for any initial condition.
Besides, the model parameters are fully interpret-
able as physico-chemical significance, being inde-
pendent on the drug initial load. The disadvantage
relates to the steady experimental and computa-
tional efforts to identify and verify all model pa-
rameters. The EKM can be easily extended for ap-
proaching porous support particles of variate geom-
etry (thin sheet, rectangular parallelepiped, cylinder
of finite or infinite length, sphere), by simply adapt-
ing the particle effectiveness and external diffusivity
evaluations for known initial and boundary condi-
tions.27,28
Factors influencing the drug
release rate
In the pre-programmed drug delivery from in-
organic porous supports, the release rate is adjusted
by the system characteristics controlling the diffu-
sion in the matrix, and eventually across the support
membrane. The main factors influencing the pro-
cess are the following:1–3,5,14,21,22,29
– crystalline / amorphous structure of the sup-
port;
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T a b l e 1 – Extended kinetic model (EKM) describing the drug adsorption-desorption and diffusional transport through the porous
support (see notations of Fig. 1; after Maria et al.13,26)
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– support texture (porosity, BET surface, pore
volume, size and distribution, tortuosity);
– support size and shape (spherical, cylindrical
tablet, thin film);
– the way to adsorb the drug on the support;
– size (cross diameter) and chemical structure
(functional groups, heteroatoms) of the drug mole-
cule;
– initial load / maximum uptake capacity of the
drug on the (functionalized) support;
– type of functional groups of the support sur-
face / linker and their interaction with the drug mol-
ecule;
– functionalization method (the solvent used,
and coverage degree);
– drug diffusivity and solubility in the receptor
body fluid;
– temperature, pH, and mixing degree of the
bulk (external) receptor fluid;
– body fluid characteristics (chemical / enzy-
matic activators of the drug release).
From the large numbers of factors influencing
the release rate, some are detailed below, to be fur-
ther used in the model-based evaluations of the ap-
proached irinotecan-MCM-41 release system.
Support particle size and shape
The literature data pointed out no significant
differences in the drug release time between powder
(with sub-millimetric or even 1–3 mm particle size)
and disk (13 × 3 mm) supports of comparable po-
rosity.23,29 Even if the initial release rate for spheri-
cal particles is higher due to a higher surface area to
volume ratio, no significant improvement in the re-
lease time is obtained for thin cylindrical tablets,29
due to the very slow diffusion of the drug mo-
lecules in the porous support matrix. For instance,
the effectiveness () of a 0.2 mm MCM particle is
0.01 for irinotecan, and 0.23–0.50 for cephalo-
sporins13,26 (see evaluation formula of Table 1).
The small molecular diffusivity of organic mole-
cules leads to a small effective diffusivity D A ef, of
10–10 – 10–14 m2 s–1,30 while the external mass trans-
fer coefficient ks in the liquid film is much higher
(10–5 – 10–8 m s–1) depending on the mixing effi-
ciency,31 making the external diffusional resistance
to be negligible.
Average pore diameter
The pore size (d pore ) is an important parameter
in modulating the drug release time for the case of
large drug molecules and/or small pore sizes. The
internal diffusion of the drug is hindered by several
factors, and the resulting effective diffusion coeffi-
cient Deff includes (Table 1): the molecular diffu-
sion (due to intermolecular collisions, D A ); Knudsen
diffusion (when pore diameters are of the same
magnitude as the molecular free path); surface dif-
fusion (neglected here); particle tortuosity ( p) (a
measure of the tortuous path of drug transport in
pores of geometry other than a straight cylinder);
restricted diffusion of molecules of large cross-di-
ameter (d A t, ) related to the pore diameter (configu-
rational diffusion, K r ); drug re-adsorption on the
pore walls during diffusion (K p).
22 As the pore size
becomes more comparable to the drug molecule
diameter, the release rate declines. For instance,
Horcajada et al.14 have found in the case of
ibuprofen (d A t,  5 Å) released from a modified
MCM-41 support, an average release rate ratio of
200 / 100 / 60 / 50 mg g–1 h–1 for average pore size
(Å) decreasing in the ratio of 36 / 33 / 27 / 25 re-
spectively.
Initial drug uptake on the support
Reported experiments confirmed that high ini-
tial drug loads on support (below the saturation
level) increase the drug release rate (rA ) due to a
higher concentration gradient between solid surface
(A f
sup
) and liquid bulk (Al , see Fig. 1). The release
rate can be approximated by the Fickian relation-
ship written for a spherical particle:13,26
r D A x a D AA A ef f
s
s A ef f




s = free-drug concentration at the contact
surface between support and liquid; ‘sup’ = refers
to the solid-liquid external interface; x = the diffu-
sion direction in pores). For instance, Bajpai et al.3
reported for the tetracycline release from a poly-
meric porous support an initial release rate ratio of
0.0065 / 0.004 / 0.002 mg min–1 corresponding to
initial load ratios of 66.6% / 56.6% / 43.3% respec-
tively. Similar results have been presented by Maria
et al.13 when comparing the obtained rA ,0 for vari-
ous initial irinotecan loads on a MCM-41 support.
It is to notice that the drug equilibrium levels on
solid and in liquid depend on the initial and release
conditions, liquid volume, and drug-support-liquid
interactions.
Silica support structure
Chemical composition and structure of the sup-
port is essential for its hydrophobic / hydrophilic
character, and surface availability for linkers and
drug molecules. For instance, MCM and SBA are
very stable silica supports, of highly ordered struc-
ture, with a high density of silanol groups (2.5–5
nm–2)32 easily to be functionalized:5 MCM-41 in-
cludes hexagonal 1D channels of 20–50 Å, while
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MCM-48 has a bicontinuous 3D structure and
20–50 Å pores. Similarly, SBA can present a variate
matrix structure: 1D (SBA-15) or 2D (SBA-3) hex-
agonal channels of 20–50(100) Å size, body center
arrangement of cages (SBA-16), or cubic structure
with 20–40 Å pores (SBA-1). The support matrix
characteristics can be modified by including vari-
ous atoms in the silica crystal. For instance, Ji et
al.19 inserted Al in the silica MCM-41 matrix to in-
crease its hydrophilicity, thus increasing the adsorp-
tion capacity of the support for polar molecules as
the Si/Al ratio decrease (keeping similar BET area
and pore sizes). Similarly, Li et al.16 reported a
slightly increase in the release rate of ibuprofen
from a mesoporous silica SBA-15 support doped
with Ca.
Linker type
Another way to control the drug release rate is
to modify the support surface properties by binding
functional reactive or passive groups to accommo-
date guest molecules by physico-chemical interac-
tions.1 Such modifications affect the release rate
and process specificity under certain release condi-
tions, the release rate being dependent not only on
the linker structure, but also on the surface func-
tionalization method and degree.1,15,21
For instance, Maria et al.13 modified the
MCM-41 surface either by functionalization with
the hydrophilic APTES or with the hydrophobic
VTES linker, following the grafting schema:






Compared to the basic support, the function-
alized MCM-41 presents a BET area reduced from
1010 m2 g–1 to 730–850 m2 g–1, a pore volume re-
duced from 1 cm3 g–1 to 0.52 cm3 g–1, and a pore
size reduced from 30 Å to 24–26 Å (Table 2). For
the irinotecan release at 37 °C (buffer of pH = 7.4;
dp = 0.2 mm particles), Maria et al.
13 derived
several conclusions: I) the release is favoured
by the hydrophilic surface, with an initial release
rate in a ratio of 6.32 / 5.92 / 1 for MCM-41 /
MCM-41-APTES / MCM-41-VTES supports re-
spectively (rates calculated with eq. 1), even if the
release time is practically the same (250–300 min);
ii) the drug equilibrium levels on the support con-
firm this release tendency, being very low for
MCM-41-APTES (0.01% of the initial load), com-
paratively to MCM-41-VTES (28.9% of the initial
load; Table 2). These conclusions are also reflected
by the EKM identified equilibrium constants, i.e. K
> 1 for MCM-APTES and K < 1 for MCM-VTES.






T a b l e 2 – Support characteristics, initial drug load, model parameters (k K k k1 2 1,  ), and equilibrium data for the irinotecan
release from a MCM-41 silica support (functionalized with APTES or VTES). Experimental conditions correspond to: a synthetic in-
testinal body fluid (buffer solution of 39.5 mL NaOH 0.1 M, and 50.5 mL KH2PO4 0.1 M; pH = 7.4); 37°C; drug solubility (Af
max) of
13.3 g L–1; support maximum uptake capacity (Ab
s ,max) of 40%wt.; liquid volume of 90 mL; particle diameter dp = 0.2 mm; tortuosity
p = 1.5–1.6; magnetic stirrer speed Na = 120–250 rpm; solid volumetric fraction in the reactor s = 4 · 10
–4 (L solid) (L liquid)–1; ksas





2 g–1) 1010 850 726
porosity p 0.64 0.48 0.39
drug/pore size, d dA t pore, (Å/Å) 5 / 30 5/23.2 5/26
drug load / drug mass (%wt)/(mg) 35.8 / 14.8 34.9 / 15 36.3 / 15
linker (%wt)(*) – 27.5 13.6
k1 (min
–1 L g–1) 20.091 20.091 1.268 · 104
K k k 2 1 0.241 1.752 2.533 · 10
–2
Def (m

















equilibrium ( )Al eql (g L-lq
–1) 0.156 0.165 0.118
(*) related to drug-free support.
The way to functionalize the support (by graft-
ing, coating, or co-condensation reactions) is also
responsible for the surface characteristics: homoge-
neous linker distribution, preservation of the matrix
integrity, surface coverage degree.1 For instance,
Song et al.15 revealed in the case of ibuprofen re-
lease (hydrophilic drug) from mesoporous silica
SBA-15 functionalized with APTES, that post-syn-
thesis reduces at half the release rate comparatively
to the one-pot functionalized support case (even if
the release time is practically the same, ca. 100 min).
Zeng et al.11 tested functionalization of MCM-41
with APTES by post-synthesis, co-condensation,
and solvothermal process, and concluded in the
case of aspirin release that co-condensation is the
best method to get a better delivery rate (reduced
with ca. 25%), by offering a mono-layer coverage
of the support. Doadrio et al.21 and Izquierdo-Barba
et al.10 revealed in the case of erythromycin release
from SBA-15 (36 Å pores) or MCM-48 (57 Å
pores) that an increase in the linker chain length
(from C8: octyltrimethoxysilane to C18: octadecyl-
trimethoxysilane) and the use of acetonitrile solvent
instead of toluene during surface grafting decrease
at half the drug release rate.
Linker coverage degree
and multi-functionalization
A homogeneous and highly covered surface
with a mono-layer of linker molecules is the best
option for increasing the matrix availability to the
drug molecules without decreasing too much the
pore size.1,11 The drug uptake increases with the
surface coverage up to a limit imposed by the func-
tional group density resulted from the grafting reac-
tions. For instance, in the MCM-41 case, the silanol
group density on the silica surface is very high
(2.5–5 Si-OH groups per nm2) compared to O-Si-O
(0.22 groups per nm2),32 the support displaying a
high uptake capacity for many drugs. However, ex-
periments indicate a maximum of 40–45%wt. linker
content on the support for the employed grafting
procedure.13
Incorporation of two or more functional groups
in a “one-pot” synthesis is also possible, although
the uniform disposal of functional groups and the
coverage degree are not so controlled as by the
grafting procedure. Literature includes various ex-
amples, for instance the simultaneous functionaliza-
tion with APTES and phenyl or methyl groups.1
The support bi-functionalization can be a worthy
route to adjust the hydrophobic/hydrophilic charac-
ter of the surface, thus adjusting the release rate and
the process thermodynamics (partition constant).
By using the proposed in-silico design approach,
this idea will be further developed.
In-silico design of an irinotecan
release system using functionalized
MCM-41
The chosen case study to test the in-silico de-
sign procedure is that of the irinotecan release from
a functionalized MCM-41 silica support, under the
nominal conditions specified in Table 2:13 a syn-
thetic intestinal fluid of pH = 7.4 at 37°C, by using
spherical particles of dp = 0.2 mm diameter in an
amount of 0.04% volumetric fraction in the reactor.
The surface rate constants (k1, k2) presented in Ta-
ble 2 have been estimated from separate experi-
ments at different drug loads by using unfunction-
alized support, or MCM-41 functionalized by graft-
ing reactions with APTES (in absolute ethanol) or
VTES (in n-hepatane). The hydrochloride irino-
tecan molecule (an anticancer drug) includes both
hydrophobic heterocycles (some with N), but also
hydrophilic groups (C=O, C–OH, –O–).
Taking advantage of the very good EKM ade-
quacy and robustness, an optimized irinotecan re-
lease system will be determined by simulations us-
ing MCM-41 support with hydrophilic APTES or
hydrophobic VTES functionalizations. The advan-
tage of such a rule is coming from the possibility to
investigate a wider parametric space without requir-
ing supplementary experiments, and from the possi-
bility to easily correlate the apparent variables with
the structural characteristics of the system.
Modulate the pore size
By support functionalization, the average pore
size of the MCM-41 is reduced, and so is its po-
rosity and BET area (Table 2). Depending on the
functionalization degree, the pore size declines
from 30 Å to ca. 20 Å, which is still much higher
than the drug molecule diameter (5 Å). Simulation
of irinotecan release from a MCM-41 support of
various pore sizes (10–30 Å), by keeping the same
initial drug load, clearly points out in Fig. 2 that
pore size reduction leads to a significant decline of
the release rate only when its size becomes compa-
rable to that of the drug. Under these circumstances,
a sharp decrease of the effective diffusivity D A ef, is
reported, leading to a smaller particle effective-
ness () and a slower release rate, though the pro-
cess duration for reaching the quasi-equilibrium
state is roughly the same. Such a result was proved
experimentally for the functionalized MCM-41
case, resulting any reduction in the release rate
for pores of 23–30 Å size.13 Such an experimental
and theoretical result does not confirm the conclu-
sions of Horcajada et al.14 for the case of ibuprofen
(d A t,  5 Å) release from modified MCM-41 sup-
ports, which reported a four times reduction in
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the release rate for a pore size reduction from 36 Å
to 25 Å. In the last case, it is possible that other
factors (e.g. the used surfactant) induce changes
in the surface properties leading to the reported
effect.
Modulate the initial drug load
By applying a similar procedure, the effect of







0  ) is simulated for an unfunc-
tionalized MCM-41 support under nominal condi-
tions of Table 2. The results, plotted in Fig. 3, con-
firm the tendency reported in literature of a sharp
increase in the initial release rate (rA ,0 ) with the ini-
tial drug uptake due to a higher concentration gradi-
ent between solid surface and liquid bulk. However,
the release time to reach the steady-state does not
differ significantly for a wide range of initial loads
of 0.05–0.35 g g–1 (the maximum uptake capacity
being 0.4 g g–1; other support characteristics are
kept constant). A smoother release rate is obtained for
a lower initial drug load on the support (0.05 g g–1).
The results from employing functionalized MCM-41
(with APTES or VTES) are similar, even if the re-
lease rates are higher for the MCM-41-APTES due
to the replacement of silanol (Si–OH) groups with
Si–CH2–CH2–CH2–NH2 groups leading to a more
unstable linkage of the hydrochloride irinotecan,
and to stronger interactions with the ionic fluid.
Such predictions are in agreement with the experi-
mental results of Maria et al.13 when using unfunc-
tionalized MCM-41 support with initial drug loads
of 0.25 and 0.35 g g–1.
The increase of the initial drug load affects the
equilibrium levels of the distributed drug between
phases in contact. Model-based simulations for long
release times indicate a significant increase of the
irinotecan equilibrium concentrations in liquid and
solid (Fig. 4). Experimental checks of the equilib-
rium levels have been reported for initial drug loads
of 25% (unfunctionalized support) and 35% (both
un-/functionalized supports).13 As the release is fa-
voured by the presence of APTES linker on MCM
surface, the equilibrium value in the solid is much
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F i g . 2 – Influence of the pore size on the irinotecan release
rate from a mezoporous support of MCM-41 (unfunctionalized)
in the synthetic biological fluid, for pore diameters (dpore) of
10 Å, 20 Å, and 30 Å (initial drug load of Ab
s
,0 = 35%wt.;
nominal conditions of Table 2). Concentrations are referring to
the liquid volume.
F i g . 3 – Influence of the initial drug load on the irinotecan
release rate from a mezoporous support of MCM-41 (un-
functionalized) in the synthetic biological fluid, for initial drug
load (Ab
s
,0) of 5%wt., 15%wt. and 35%wt. (pore diameters of
30 Å; nominal conditions of Table 2). Concentrations are refer-
ring to the liquid volume.
F i g . 4 – Influence of the initial drug load (Ab
s
,0) and of the
MCM-41 support functionalization on the equilibrium concen-
trations of irinotecan in solid and liquid for the following
supports: unfunctionalized MCM-41 (–––), MCM-41-APTES
(– – –), MCM-41-VTES (:) (nominal conditions of Table 2).
Concentrations are referring to the liquid volume.
lower for the MCM-41-APTES than for the
MCM-41-VTES support, and vice-versa in the bulk
liquid. This release tendency is better quantified
by the desorption-adsorption equilibrium constant
K k k 2 1 : while for the hydrophilic MCM-41-APTES
functionalization K constant is higher than unity
(1.752 in Table 2), the release tendency is lower
from the MCM-41 support (K = 0.241), and much
lower from the MCM-41-VTES support (K = 0.025).
Modulate the hydrophilic / hydrophobic
balance through bi-functionalization
An interesting possibility of adjusting the re-
lease rate is to use a support functionalized with
both hydrophilic and hydrophobic linkers. Thus, for
a specific drug, the release rate can be easily modu-
lated by changing the ratio of the two linkers on the
support, by keeping unchanged the overal surface
coverage. Bi-functionalization can be done by using
the “one-pot” synthesis, or by mixing the powder
support separately functionalized with each linker
in the desired proportion.
To in-silico check this alternative, one consid-
ers the MCM-41 support with nominal characteris-
tics of Table 2 (APTES column), but functionalized
with both APTES and VTES, by keeping the over-
all coverage constant (27.5%wt). One assumes that
the drug molecules preferentially bond to the free
linker molecules of the support surface, while
adsorption-desorption on other less active sur-
face sites is of minor importance, being included
in the apparent adsorption-desorption rate con-
stants:
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For a bi-functionalized porous support with
linkers L1 and L2, one considers a non-competitive
drug linking process, the overall drug adsorption
and desorption rates becoming:
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Consequently, for a constant surface coverage
and denoting with g L L
s s
1 1 	 	 the gravimetric
fraction of L1 active sites (L2 sites fraction being
g gL L2 11 
 ), the average adsorption and desorp-
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K k kL L L1 2 1 1 1 , , ; K k kL L L2 2 2 1 2 , , .
(being assumed the equality of the ratios
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By applying this averaging procedure for the
irinotecan adsorption-desorption on a bi-functiona-
lized MCM-41-APTES-VTES support, one can
simulate the drug release under the nominal condi-
tions of Table 2 (centre column) and with known
rate constants for every individual linker. By keep-
ing the overall linker coverage of 27.5%wt., but
varying the APTES linker fraction (gAPTES) from 0
to 1 one obtains the release curves of Fig. 5, which
lead to several conclusions.
i) As expected, the irinotecan release rate from
the bi-functionalized MCM-41 support is as high as
the gravimetric fraction of APTES on the surface
increases. Even more important, this dependence is
strongly non-linear (roughly logarithmic): for up to
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F i g . 5 – Simulation of the irinotecan release from a
MCM-41 support, bi-functionalized with APTES and VTES, in
the synthetic biological fluid, for initial drug load (Ab
s
,0) of
35%wt. The figured numbers on release curves denote the
APTES wt. fraction on the covered surface with linkers (total
linker coverage of 27.5%wt.; pore diameter dpore = 24 Å; po-
rosity p = 0.48; particle diameter dp = 0.2 mm; solid fraction
in the reactor s = 4 · 10
–4 L L–1). Concentrations are referring
to the liquid volume.
50% APTES the release curve is practically un-
changed; in the range of 90–100% APTES the re-
lease curves change dramatically, in an accelerated
way as gAPTES gets closer to 1. In absolute terms, for
a 90%wt. APTES and 10%wt. VTES coverage,
80% of the irinotecan is released over 6 hrs. For
comparison, over the same time interval, 72% of
the drug is released for a 50%wt. coverage with
APTES, but 92% of the drug is released for a
98%wt. coverage with APTES and 2% with VTES.
In such a manner, the release time, rate, and the
drug level in the liquid can be easily modulated by
simply changing the ratio of hydrophilic / hydro-
phobic linkers on the support. It is also to observe
that a smoother release rate can be achieved only
for bi-functionalized supports with less than
50%wt. APTES coverage.
ii) An explanation of the logarithmic-like de-
pendence of the drug release trajectory on the APTES
fraction on the support can be offered by the
pseudo-first order release rate for drug concentrations
in the receptor fluid far from the saturation level. The
process thermodynamics is also nonlinearly influ-
enced by the gAPTES due to the hyperbolic dependence
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It is to notice that the mono-layer functionaliza-
tion degree on a silica support is however limited by
the available density of silanol groups of the surface
(e.g. 2.5–5 Si-OH groups per nm2 for MCM),32 and
by the functionalization procedure.
Even if there is yet no experimental proof re-
lated to the predicted behaviour of the bi-function-
alized MCM-41 support, the EKM simulations are
expected to be well oriented, being based on consis-
tent and robust parameters separately checked for
the two types of functionalizations.
Conclusions
A mechanism-based adequate kinetic model
describing the drug release from a porous function-
alized support can be a worthy instrument for pre-
dicting the process efficiency when using modified
structures and operating conditions. Such in-silico
evaluations can be realized if the model includes
enough significant structural parameters of the sys-
tem, eventually directing the experimental research
toward finding an optimized drug-linker-support
configuration that realizes the desired release rate.
The EKM of Maria et al.13 approached in this study
can offer the possibility to evaluate the influence of
some structural and operational process parameters
on the release efficiency and thermodynamic equi-
librium, such as: pore size, support size and geome-
try, support modifications (e.g. via surface rate con-
stants), porosity (pore volume), linker type, func-
tionalization degree, linker ratio for a bi-function-
alized support, drug molecule size and type, mixing
conditions, temperature, pH.
The influence of some mentioned parameters
are investigated in the case of irinotecan release from
a mesoporous silica MCM-41 support functionalized
with the hydrophobic APTES or hydrophobic VTES
linkers, in a finite volume of synthetic body fluid at
37°C. Model based simulations results indicate some
interesting conclusions concerning the release pro-
cess: I) sub-millimetric particle size presents any sig-
nificant influence on the release rate; ii) pore size ex-
erts a significant influence only when it becomes
comparable to the drug molecular diameter; iii) an
increase of the initial drug load on the support leads
to a sharp increase of the initial release rate but
to a less smoother release; iv) the initial drug
load strongly affects the equilibrium concentrations
of the drug in support and liquid; v) the linker
type strongly affects the release rate and equilibrium
state, e.g. a high release tendency of irinotecan
from MCM-41-APTES and much lower from
MCM-41-VTES support; vi) changing the hydro-
phobic / hydrophilic linkers’ ratio for a bi-function-
alized MCM-41 support leads to a nonlinear varia-
tion of the release rate (and equilibrium state); vii) a
smoother irinotecan release from a bi-functionalized
support can be realized for a quasi-even surface cov-
erage with the two linkers, at a moderate lower ini-
tial drug load on the carrier. Experimental checks of
Maria et al.13,26 validated some of the model predic-
tions (i.e. influence of the pore size, initial drug load,
and functionalization type on the process dynamics),
some others remaining to be further confirmed.
Combinations of effects can be easily simulated
with EKM, by simultaneously varying the process /
support parameters, with also including factors not
approached in this study (e.g. particle size and
shape). The analysis can be easily extended for ap-
proaching other porous delivery systems of simple or
multi-functionalization type, and for various support
geometries (e.g. cylindrical tablets) without major
changes in the model relationships.
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S y m b o l s
Ab
s 
 bound-drug on the support sites, g (L-lq)–1
A f
s 
 free-drug at the contact surface between support




 free-drug at the solid-liquid external interface,
g (L-lq)–1
A l 








 saturation level for the drug in liquid, g (L-lq)–1
as 
 liquid-solid specific interfacial area, m
–1
Da 
 stirrer diameter, m
DA 
 molecular diffusivity of A in the receptor fluid,
m2 s–1
dp 
 particle average diameter, m
dA,t 
 drug molecule width, m
dpore 
 pore average diameter, m
g 
 gravimetric fraction; gravitational acceleration,
m s–2
Kp 
 partition coefficient for drug adsorption on the
pore walls
Kr 
 restriction coefficient for the hindered diffusion
of large molecules vs. pore diameter
ks 
 liquid-solid mass transfer coefficient (on liquid
side), m s–1
k 
 rate constants, (L-lq) g–1 s–1
Jdiff 
 diffusional rate of drug molecules in pores,
g (L-lq)–1 s–1
M(t) 
 cumulative mass of drug released at time t in liq-
uid
M 
 cumulative mass of drug released at infinite time
in liquid
Na 
 stirrer rotational speed, rpm
NP 
 dimensionless power number
33
n 
 Korsmeyer-Peppas model exponent
Pa 
 power transmitted in the liquid by the magnetic
stirrer34, W
Re dL L p L L ( )
4 3 3  
 Reynolds number (liquid)
rA 
 adsorption / desorption rate of A species on the
solid support, g (L-lq)–1 s–1
Sc DL L L A  ( ) 
 Schmidt number (liquid)





 liquid superficial velocity (due to the mixing),
m s–1
VTP 
 total volume of pores, m
3 g–1
x 
 diffusion direction, m










	 l f f
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max 
 desorption potential due to the unsatu-






 free sites on the support internal inter-
face, g (L-lq)–1
 
 dynamic viscosity, N s m–2
 
 density, g L–1
L 





 Carman shape factor
28




















 referred to the solid phase, or to the interface, or
to the steady-state
S u p e r s c r i p t s
l 




 at the solid-liquid external interface
s 
 referring to the solid
– 
 average value




 desorption activators in the receptor liquid
EKM
 extended (compartmented) kinetic model
MIP 
 molecularly imprinted systems
VTES 
 triethoxyvinylsilane
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